| Patient | Duke Kahanamoku |
|---|---|
| Date of birth | 1959-08-24 |
| Identifiers | MRN HR-ML050-SYN; SSN (made up) 000-50-6847 |
| Document date | 2026-04-27 |
| Author | Kawika Lindgren-Morrison, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review, five days after the sick visit. [S]
Mr. Kahanamoku returns two weeks after spironolactone was added and five days after his sick visit for vomiting and diarrhea, when his potassium was 5.5 mmol/L. He followed the sick-day card: he held empagliflozin, furosemide, spironolactone and sacubitril-valsartan, took half-dose carvedilol for two days and drank oral rehydration solution. The illness settled after three days, and he restarted all his medicines two days ago. His home weight is 93 kg and steady, he has no swelling, orthopnea or lightheadedness, and he walks a mile on the flat without stopping. He is eager to be back in the ocean and asks how to do it safely. [S]
| Element | Detail |
|---|---|
| Since the sick visit | Medicines held for three days, restarted two days ago; no further vomiting or diarrhea |
| Home weight | 93 kg, steady |
| Function | Walks a mile on the flat; NYHA class II |
| KCCQ-12 | 66, from 56 |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No vomiting or diarrhea since three days ago; eating normally |
| Cardiovascular | Negative | No chest pain, palpitations, ankle swelling or lightheadedness |
| Respiratory | Negative | No breathlessness at rest; sleeps flat |
| Musculoskeletal | Negative | No muscle aches on atorvastatin 80 mg |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 to 2026-03-16 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Metoprolol tartrate 25 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 2021-06-21 to 2026-03-30 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 to 2026-03-30 | completed | S |
| Furosemide 40 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 2026-03-16 to 2026-04-27 | completed | S |
| Furosemide 20 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 2026-04-27 | active | S |
| Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril | One tablet twice daily | Oral route | 2026-03-30 to 2026-09-28 | completed | S |
| Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrate | One tablet twice daily with food | Oral route | 2026-03-30 to 2026-04-13 | completed | S |
| Carvedilol 6.25 mg oral tablet, one tablet twice daily with food | One tablet twice daily with food | Oral route | 2026-04-13 to 2026-04-27 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet twice daily with food | One tablet twice daily with food | Oral route | 2026-04-27 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking | One tablet daily, with sick-day rules | Oral route | 2026-03-30 | active | S |
| Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily | One-half tablet daily | Oral route | 2026-04-13 | active | S |
| Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apart | Two infusions two weeks apart | Intravenous route | 2026-03-30 to 2026-04-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-27 | Body height | 185 | cm | S |
| 2026-04-27 | Body weight | 93 | kg | S |
| 2026-04-27 | Body mass index (BMI) [Ratio] | 27.2 | kg/m2 | S |
| 2026-04-27 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-04-27 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-04-27 | Heart rate | 68 | /min | S |
| 2026-04-27 | Respiratory rate | 16 | /min | S |
| 2026-04-27 | Body temperature | 36.6 | Cel | S |
| 2026-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-27 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-27 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.2 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 67 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-27 | Glucose [Mass/volume] in Serum or Plasma | 97 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-27 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-04-27 | Cholesterol [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 62 | mg/dL | Secondary-prevention goal below 70 mg/dL | Normal | S |
| 2026-04-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 45 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-04-27 | Triglyceride [Mass/volume] in Serum or Plasma | 115 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-55 U/L | Normal | S |
| 2026-04-27 | Overall summary score [KCCQ-12] | 66 | {score} | S |
Vital signs recorded on 2026-04-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 112/70, pulse 68; weight 93.0 kg |
| Orthostatic vital signs | Standing at three minutes 108/68 mmHg without symptoms |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; no S3; apical systolic murmur |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determined | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction. |
| Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1952 | active | confirmed | I25.2 | S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history. |
| Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosis | active | confirmed | I50.22 | S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime. |
| Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%) | active | confirmed | E61.1 | S — Synthetic finding at the heart failure workup. |
| Viral gastroenteritis for two days, with volume depletion, potassium 5.5 mmol/L and a rise in creatinine on sacubitril-valsartan, spironolactone, empagliflozin and furosemide; settled with sick-day rules | resolved | confirmed | A08.4 | S — Synthetic intercurrent problem at an unscheduled visit; it follows from his heart failure medicines and does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and heart rate (seated and standing) | Every visit | Completed today | 112/70 mmHg, pulse 68; standing 108/68 without symptoms |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 93.0 kg; jugular venous pressure not raised; no edema; NYHA II |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, ARNI, MRA or SGLT2 inhibitor; then every three to six months | Completed today | Two weeks after spironolactone and two days after restarting held medicines: sodium 137, potassium 4.8, creatinine 1.20 mg/dL (eGFR 67), magnesium 2.0. The one-to-two-week check after spironolactone was also covered by the sick-visit panel at nine days (potassium 5.5 during volume depletion) |
| Medication safety | Guideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target doses | Every two weeks during titration | Completed today | Carvedilol raised today; sacubitril-valsartan increase planned in two weeks by the nurse, with a panel a week later |
| Medication safety | MRA and ARNI: potassium and kidney function during illness | Every visit | Completed today | Sick-day rules used correctly; potassium back to 4.8 |
| Laboratory | Lipid panel | Four to twelve weeks after a statin change, then every three to twelve months | Completed today | Six weeks after atorvastatin 80 mg: LDL 62 mg/dL, total cholesterol 130, HDL 45, triglycerides 115; ALT 31 U/L |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Completed today | 66, from 56 |
| Imaging | Echocardiogram | At diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained change | Not indicated | Repeat after three to six months of optimized therapy |
| Examination | Primary-prevention ICD evaluation (and CRT if QRS is wide) | After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarction | Due | After at least 90 days of optimized therapy |
| Referral | Cardiac rehabilitation for heart failure | When eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeks | Ordered | Program booked from late May, when he becomes eligible |
| Self-management | Self-care: daily weights, sodium, sick-day rules and symptoms to report | Every visit | Completed today | Sick-day card used well; daily weights; dry weight 93 kg |
| Self-management | Culturally safe care: ʻohana involvement as he chooses; his own healing practices | Every visit | Completed today | No Native Hawaiian practices raised today; offer remains open |
Goal progress:
Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026)
Follow-up: Heart failure nurse call in two weeks to raise sacubitril-valsartan, with a metabolic panel one week later. Cardiac rehabilitation from late May. Annual wellness visit in September; heart failure review in about five months with a repeat echocardiogram. Next scheduled visit 2026-09-14: subsequent annual wellness visit. [S]